Emerging evidence reveals a clinically significant rebound effect following the discontinuation of glucagon-like peptide-1 ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) ...

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga ...

What else is there to share? As it happens, quite a lot. Last time I spoke about the diagnosis of Young Onset Parkinson’s disease (YOPD), how this presented several day-to-day challenges from securing ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research ...

TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD) is set to revolutionise early ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking a ...

Co-founded by Landmark BioVentures and researchers from Aix-Marseille University, Massalia Therapeutics builds on 20 years of ...